Medlab Clinical Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wir verfügen derzeit nicht über ausreichende Analystenabdeckung, um Wachstum und Umsatz für Medlab Clinical zu prognostizieren.

Wichtige Informationen

-44.7%

Wachstumsrate der Gewinne

-44.7%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	15.3%
Wachstumsrate der Einnahmen	41.7%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	04 May 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future

Nov 22

Recent updates

Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now

Oct 06

Gewinn- und Umsatzwachstumsprognosen

ASX:MDC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (AUD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
6/30/2024	4	-22	N/A	N/A	1
6/30/2023	7	-14	N/A	N/A	1
6/30/2022	2	-8	-9	-9	N/A
3/31/2022	1	-9	-10	-10	N/A
12/31/2021	4	-12	-11	-11	N/A
9/30/2021	4	-12	-11	-11	N/A
6/30/2021	1	-10	-10	-10	N/A
3/31/2021	1	-10	-9	-9	N/A
12/31/2020	1	-11	-8	-8	N/A
9/30/2020	2	-12	-10	-9	N/A
6/30/2020	3	-13	-11	-10	N/A
3/31/2020	4	-12	-11	-11	N/A
12/31/2019	4	-12	-12	-12	N/A
9/30/2019	5	-10	-11	-11	N/A
6/30/2019	5	-8	-11	-10	N/A
3/31/2019	5	-7	-9	-9	N/A
12/31/2018	5	-6	-7	-7	N/A
9/30/2018	4	-5	-6	-6	N/A
6/30/2018	4	-5	-5	-5	N/A
3/31/2018	4	-4	-5	-5	N/A
12/31/2017	5	-4	-5	-5	N/A
9/30/2017	5	-4	-4	-4	N/A
6/30/2017	4	-4	-4	-4	N/A
3/31/2017	4	-4	-4	-4	N/A
12/31/2016	4	-4	-4	-4	N/A
9/30/2016	3	-4	-4	-4	N/A
6/30/2016	3	-3	-4	-4	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: MDC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: MDC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: MDC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: MDCDie Einnahmen des Unternehmens (41.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Australian (5.7% pro Jahr).

Hohe Wachstumseinnahmen: MDCDie Einnahmen des Unternehmens (41.7% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von MDC in 3 Jahren voraussichtlich hoch sein wird

Medlab Clinical Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates upgraded to AU$2.29 loss, revenue downgraded

Consensus forecasts updated

Price target decreased to AU$18.84

Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future

Recent updates

Consensus EPS estimates upgraded to AU$2.29 loss, revenue downgraded

Consensus forecasts updated

Price target decreased to AU$18.84

Medlab Announces Interim Readout of Rwe Medcare Study

Medlab Clinical Limited Receives UK Import Permission from MHRA for Nanabis

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Medlab Clinical Limited Provides NanoCelle Nasal RNA (Nucleid Acid) Program Update

Medlab Clinical Limited Provides NanaBis and NanoCBD Clinical Development Update

Less than half of directors are independent

Medlab Clinical Limited Announces the Resignation of Laurence McAllister as Non-Executive Director

Full year 2022 earnings: Revenues exceed analyst expectations

Medlab Clinical Limited, Annual General Meeting, Sep 30, 2022

Medlab Clinical Ltd Announces the European Patent Office Has Formalised ACCEPTANCE of the Depression Patent, and Within the Next 2-3 Months Will Be Granted

Medlab Clinical Limited Appoints Mohit Gupta as an Independent Non-Executive Director, Effective August 8, 2022

Medlab Clinical Ltd Updates Shareholders on the Progress of Our NanoCelle NanaBis Program

Medlab Clinical Ltd Announces Update on Progression of NanoCelle NASAL COVID-19 Vaccine Program

Less than half of directors are independent

Medlab Clinical Ltd Announces Update on NanoCBDTM

Medlab Clinical Ltd Announces the Receipt of "Favorable Opinion" Status from the UK Research Ethics Committee for the Forthcoming Nanabistm Phase 3 Trial, with No Additional Conditions or Submission Required

Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now

Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?

Full year 2021 earnings released: AU$0.042 loss per share (vs AU$0.059 loss in FY 2020)

Medlab Receives Phase 3 NanaBi Trials Approval from the Australian Government, with Clinical Trials Number for Cancer Bone Pain

Australian Ethics Grants Approval for Medlab's NanaBisTM PIII Australian Sites

CFO, Company Secretary & COO has left the company

Medlab Clinical Limited announced that it expects to receive AUD 15 million in funding

Medlab Clinical Limited Appoints Cheryl Maley as an Independent Non-Executive Director

First half 2021 earnings released: AU$0.019 loss per share (vs AU$0.033 loss in 1H 2020)

What We Learned About Medlab Clinical's (ASX:MDC) CEO Pay

Medlab Executes Australian Exclusive Non-Binding Heads of Agreement with Arrotex Australia Group Australia Pty Ltd

Medlab Clinical Limited Receives Positive Depression Trial Prelim Results

New 90-day high: AU$0.36

Medlab Clinical Announces US FDA Grants Investigational New Drug (IND) Status for Nanabistm

Medlab Clinical (ASX:MDC) Share Prices Have Dropped 69% In The Last Three Years

Medlab Clinical Provides an Update on Clinical and Pre-Clinical Programs Currently Underway

Medlab Clinical Limited Announces NanaBis Observational Study Progression Report

New 90-day high: AU$0.26

Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future

Medlab Clinical Limited Announces NanaBisTM PIII Trial Launching in the Uk with Support from the National Institute for Health Research

New 90-day high: AU$0.21

Full year earnings released - AU$0.059 loss per share

Medlab Clinical Limited has completed a Follow-on Equity Offering in the amount of AUD 1.570476 million.

Medlab Clinical Limited announced that it has received AUD 5.397603 million in funding

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken